Sozinibercept Combination Therapy for Neovascular Age-related Macular Degeneration Phase 2b Study Subgroup Analysis by Lesion Type

Sozinibercept Combination Therapy for Neovascular Age-related Macular Degeneration : Phase 2b Study Subgroup Analysis by Lesion Type

BACKGROUND AND OBJECTIVE: The purpose of this study was to evaluate the angiographic predictors of response to the anti-vascular endothelial growth factor-C/-D agent, sozinibercept

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - (2025) vom: 01. Feb., Seite 1-10
1. Verfasser: Wykoff, Charles C (VerfasserIn)
Weitere Verfasser: Jackson, Timothy L, Price, Clare F, Baldwin, Megan E, Leitch, Ian M, Slakter, Jason
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2025
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article
Beschreibung
Zusammenfassung:BACKGROUND AND OBJECTIVE: The purpose of this study was to evaluate the angiographic predictors of response to the anti-vascular endothelial growth factor-C/-D agent, sozinibercept
PATIENTS AND METHODS: Prespecified and post hoc subgroup analyses of a phase 2b, randomized, double-masked, sham-controlled trial of 240 participants with treatment-naïve neovascular age-related macular degeneration, comparing monthly intravitreal sozinibercept 0.5 mg or 2 mg, plus ranibizumab 0.5 mg, versus monthly ranibizumab monotherapy
RESULTS: Visual acuity benefits at week 24 were greatest in participants with occult lesions receiving 2 mg sozinibercept combination therapy (+15.65 [n = 53] letters versus +9.62 [n = 51] with ranibizumab monotherapy; least squares mean difference +6.03; P = 0.0009). A composite analysis of occult and minimally classic lesions excluding retinal angiomatous proliferation (n = 175/240) also favored sozinibercept over control (+16.08 versus +10.34 letters; +5.74; P = 0.0002). Structural outcomes mirrored sozinibercept visual acuity benefits, with less leakage and smaller lesions on multimodal imaging
CONCLUSION: Angiographic lesion characteristics were found to predict the response to sozinibercept combination therapy. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.]
Beschreibung:Date Revised 25.02.2025
published: Print-Electronic
Citation Status Publisher
ISSN:2325-8179
DOI:10.3928/23258160-20250108-04